Epitalon offers something remarkable
And as an obstetrician who has sat at the bedside of thousands of women in the most joyous, the most horrible, the most gut-wrenching, the most mundane, the most, I cannot every emotion, every possible scenario at the bedside through the birth of children and to accuse obstetricians of execution of newborns is ridiculous
EPS: ~$23.50 Forward P/E: ~42 (premium justified by growth) PEG Ratio: ~0.9 (attractive given growth rate) Long-Term Track Record Performance: 52-Week Range: $623.78 - $999.92 1-Year Return: +20-25% (volatile but trending up) Market Leadership: Approaching $1 trillion valuation Dividend Profile: Current Yield: ~0.6% (modest but growing) Annual Dividend: $6.00 per share Growth Rate: Consistently increasing ~15% CAGR The dividend is small now, but management prioritizes reinvestment in R&D while rewarding long-term shareholders with steady increases
The conversation explores how reactive oxygen species (ROS) arise in metabolism, the central role of glutathione as a natural antioxidant, why high-dose antioxidant supplements can backfire, and emerging strategies that target cancers reliance on antioxidant systems
[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Stanley C.A., DeLeeuw S., Coates P.M., Vianey-Liaud C., Divry P., Bonnefont J.P., Saudubray J.M., Haymond M., Trefz F.K., Breningstall G.N., et al
As DNA damage accumulates with age and exercise, PARP activity increases which can deplete NAD+ rapidly